Sulfonamide-induced hemolytic anemia and hemoglobin Hasharon

Area of Science:

• Hematology
• Pharmacology
• Biochemistry

Background:

• Hemoglobin Hasharon is an abnormal hemoglobin variant.
• Sulfisoxazole is a sulfonamide antibiotic.
• Drug-induced hemolytic anemia is a serious adverse reaction.

Purpose of the Study:

• To investigate the mechanism of sulfisoxazole-induced hemolytic anemia in a patient with Hemoglobin Hasharon.
• To determine the interaction between sulfisoxazole and Hemoglobin Hasharon.

Main Methods:

• Erythrocyte incubation with sulfisoxazole.
• Heat stability tests of Hemoglobin Hasharon and Hemoglobin A.
• Analysis of heme-globin bond stability.

Main Results:

• Sulfisoxazole induced preferential oxidation and precipitation of Hemoglobin Hasharon.
• The alpha47 substitution in Hemoglobin Hasharon likely mediates drug interaction.
• The heme-globin bond in Hemoglobin Hasharon was labilized by the drug.

Conclusions:

• Hemoglobin Hasharon carriers are at risk of severe hemolytic anemia upon sulfisoxazole ingestion.
• The alpha47 substitution influences hemoglobin's interaction with drugs.
• Further research is needed to elucidate the exact mechanism of drug-induced heme-globin bond labilization.